{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:30:58Z","timestamp":1792074658113,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1053\/j.semnuclmed.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T22:14:52Z","timestamp":1312323292000},"page":"354-363","source":"Crossref","is-referenced-by-count":28,"title":["Iodine-131\u2013labeled Meta-Iodobenzylguanidine Therapy of Children with Neuroblastoma: Program Planning and Initial Experience"],"prefix":"10.1053","volume":"41","author":[{"given":"Suzanne","family":"Shusterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick D.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Royal T.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Drubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic H.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ted","family":"Treves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2011.06.001_bib1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198107023050103","article-title":"Scintigraphic localization of pheochromocytoma","volume":"305","author":"Sisson","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib5","first-page":"773","article-title":"Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine","volume":"25","author":"Kimmig","year":"1984","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/j.semnuclmed.2011.05.001","article-title":"Pediatrics: Diagnosis of neuroblastoma","volume":"41","author":"Sharp","year":"2011","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21932","article-title":"(123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial","volume":"52","author":"Vik","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib8","first-page":"244","article-title":"Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma","volume":"35","author":"Matthay","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00000421-199206000-00009","article-title":"131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma","volume":"15","author":"Hutchinson","year":"1992","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0304-3959(94)00186-I","article-title":"Rapid, reproducible pain relief with [131I]iodine-meta-iodobenzylguanidine in a boy with disseminated neuroblastoma","volume":"60","author":"Westlin","year":"1995","journal-title":"Pain"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib11","first-page":"S65","article-title":"The treatment of neuroblastoma with [131I] MIBG at diagnosis","volume":"39","author":"Troncone","year":"1995","journal-title":"Q J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib12","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.bjc.6694223","article-title":"131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients","volume":"81","author":"Garaventa","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib13","first-page":"77","article-title":"Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours","volume":"44","author":"Castellani","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00043426-200310000-00005","article-title":"Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma","volume":"25","author":"Kang","year":"2003","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.1992.10.12.1889","article-title":"Phase I\/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom children's Cancer Study Group investigation","volume":"10","author":"Lashford","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.1998.16.1.229","article-title":"Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma","volume":"16","author":"Matthay","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2006.09.3484","article-title":"Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma","volume":"25","author":"Matthay","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2007.15.7628","article-title":"Iodine-131\u2013metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib19","doi-asserted-by":"crossref","unstructured":"Johnson K, McGlyn B, Saggio J, et al: Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed\/refractory neuroblastoma. Pediatr Blood Cancer, Apr 14, 2011, Epub ahead of print","DOI":"10.1002\/pbc.23062"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0959-8049(95)00048-N","article-title":"A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin","volume":"31A","author":"Mastrangelo","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1005770405844","article-title":"Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma","volume":"31","author":"Mastroangelo","year":"1997","journal-title":"J Neuro Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1054\/bjoc.2000.1645","article-title":"Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy","volume":"84","author":"Mastrangelo","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cbr.2005.20.195","article-title":"Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma","volume":"20","author":"Gaze","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-2949","article-title":"Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems","volume":"17","author":"More","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0959-8049(98)00130-0","article-title":"Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy","volume":"34","author":"Klingebiel","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib26","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2002.08.124","article-title":"Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma","volume":"20","author":"Yanik","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study","volume":"24","author":"Matthay","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2011.06.001_bib28","first-page":"S76","article-title":"The application of ALARA for occupational exposures","volume":"78","year":"2000","journal-title":"Health Phys"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299811000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:54:49Z","timestamp":1543625689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299811000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0001299811000717"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2011.06.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}